Innogenetics NV is an international in vitro diagnostics company, with headquarters in Ghent, Belgium. The company develops and markets diagnostic assays in the fields of infectious diseases, oncology, neurodegeneration, transplantation and genetic testing, with a special focus on molecular diagnostics and multiparameter testing. The company was acquired in September 2010 by the Japanese Fujirebio Inc. Group. The CEO of Innogenetics NV is Christiaan De Wilde.
Contents |
Innogenetics was founded on 18 July 1985, by Erik Tambuyzer, Hugo Van Heuverswyn and Rudi Mariën. In 1992, the company launched the first commercial tests for cystic fibrosis in Europe (INNO-LiPA CFTR) and in 1993 the first commercial test for Hepatitis C virus (HCV) genotyping worldwide (INNO-LiPA HCV). In 1995, the first commercial Alzheimer’s disease research test for hTau was launched (INNOTEST hTau Ag). In 1998, the company launched the first commercial Alzheimer’s disease research test for β-Amyloid and in 2002 the first commercial test for Hepatitis B virus (HBV) genotyping (INNO-LiPA HBV Genotyping).
The company was one of the first biotech companies to be listed on a European stock exchange, in 1996 it was the first biotech company listed on EASDAQ, now NASDAQ Europe. Until 2008 Innogenetics had its shares traded on Euronext Brussels. On 1 October 2007, the therapeutics division was separated into a new company GENimmune NV for the development of immune therapeutics.
Solvay Pharmaceuticals, a subsidiary of the Solvay Group, the chemical and pharmaceutical group, announced in September 2008 that it had acquired Innogenetics in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares.
Today Innogenetics NV is a member of the Fujirebio Inc. group, a Japanese daughter company of Miraca Holdings.